| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alberto Parabiaghi, Barbara D'Avanzo, Mauro Tettamanti, Angelo Barbat. The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. Contemporary clinical trials. vol 32. issue 5. 2011-12-06. PMID:21554991. |
the gisas study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Alberto Parabiaghi, Barbara D'Avanzo, Mauro Tettamanti, Angelo Barbat. The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. Contemporary clinical trials. vol 32. issue 5. 2011-12-06. PMID:21554991. |
the primary aim of the present study is to compare the effectiveness of haloperidol, olanzapine and aripiprazole in a representative sample of schizophrenia patients. |
2011-12-06 |
2023-08-12 |
human |
| Alessandro Zuddas, Roberta Zanni, Tatiana Usal. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 21. issue 8. 2011-11-28. PMID:21550212. |
sgas efficacy on mania, extreme mood variability, irritability, aggression and disruptive behavior appears to be greater than for psychotic symptoms in schizophrenia: average nnt was 2-5, whereas for schizophrenia it varies between 3 for risperidone and 10 for olanzapine, quetiapine, and aripiprazole. |
2011-11-28 |
2023-08-12 |
Not clear |
| Ravindra B Belgamwar, Hany George G El-Saye. Aripiprazole versus placebo for schizophrenia. The Cochrane database of systematic reviews. issue 8. 2011-10-27. PMID:21833956. |
aripiprazole versus placebo for schizophrenia. |
2011-10-27 |
2023-08-12 |
Not clear |
| Corrado Barbui, Cinzia Baschirotto, Andrea Ciprian. Review: is aripiprazole as effective as risperidone in people with schizophrenia? Evidence-based mental health. vol 13. issue 2. 2011-10-26. PMID:21856614. |
review: is aripiprazole as effective as risperidone in people with schizophrenia? |
2011-10-26 |
2023-08-12 |
Not clear |
| Tamara Melnik, Bernardo Garcia Soares, Maria Eduarda Dos Santos Puga, Alvaro Nagib Atalla. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. Sao Paulo medical journal = Revista paulista de medicina. vol 128. issue 3. 2011-10-13. PMID:20963366. |
efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. |
2011-10-13 |
2023-08-12 |
Not clear |
| Takahiro A Kato, Akira Monji, Keiji Yasukawa, Yoshito Mizoguchi, Hideki Horikawa, Yoshihiro Seki, Sadayuki Hashioka, Youn-Hee Han, Mina Kasai, Noriyuki Sonoda, Eiichi Hirata, Yasutaka Maeda, Toyoshi Inoguchi, Hideo Utsumi, Shigenobu Kanb. Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia. Schizophrenia research. vol 129. issue 2-3. 2011-10-13. PMID:21497059. |
our results imply that aripiprazole may have psychotropic effects by reducing the microglial oxidative reactions and following neuronal reactions, which puts forward a novel therapeutic hypothesis in schizophrenia research. |
2011-10-13 |
2023-08-12 |
Not clear |
| Alessandro De Risio, Angelo Pancheri, Giovanna Simonetti, Diana Giannarelli, Luciana Stefanutto, Bruno Gentil. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 4. 2011-09-13. PMID:21447367. |
add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. |
2011-09-13 |
2023-08-12 |
Not clear |
| Alessandro De Risio, Angelo Pancheri, Giovanna Simonetti, Diana Giannarelli, Luciana Stefanutto, Bruno Gentil. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 4. 2011-09-13. PMID:21447367. |
in this retrospective case series, we investigated the change in bprs scores and metabolic features like bmi, fasting glucose, total and ldl cholesterol, triglycerides, functional outcome honos rome and psp scores after aripiprazole augmentation in 16 persons with treatment-resistant schizophrenia who were already treated with clozapine. |
2011-09-13 |
2023-08-12 |
Not clear |
| Mei Han, Xu-Feng Huang, Chao Den. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. The international journal of neuropsychopharmacology. vol 12. issue 7. 2011-09-06. PMID:19203411. |
aripiprazole has been used effectively to treat schizophrenia in the clinic; however, its mechanisms of action are not clear. |
2011-09-06 |
2023-08-12 |
Not clear |
| Mei Han, Xu-Feng Huang, Chao Den. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. The international journal of neuropsychopharmacology. vol 12. issue 7. 2011-09-06. PMID:19203411. |
selectively reducing dopamine synthesis in vta is a possible therapeutic mechanism for the long-term efficacy of aripiprazole in controlling schizophrenia symptoms with reduced extrapyramidal side-effects. |
2011-09-06 |
2023-08-12 |
Not clear |
| Kazuo Yamada, Yasuyuki Makihara, Yoshiki Imamur. Effectiveness of aripiprazole for medication overuse headache: a case report. Psychiatry and clinical neurosciences. vol 65. issue 3. 2011-08-30. PMID:21507137. |
aripiprazole, a dopamine d2 receptor partial agonist, has been used to treat schizophrenia and might be effective for alcohol dependence and craving. |
2011-08-30 |
2023-08-12 |
Not clear |
| Rohan Ganguli, Jaspreet S Brar, Ronald Garbut, Chung-Chou H Chang, Ranita Bas. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clinical schizophrenia & related psychoses. vol 5. issue 2. 2011-08-30. PMID:21693430. |
changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. |
2011-08-30 |
2023-08-12 |
Not clear |
| Rohan Ganguli, Jaspreet S Brar, Ronald Garbut, Chung-Chou H Chang, Ranita Bas. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clinical schizophrenia & related psychoses. vol 5. issue 2. 2011-08-30. PMID:21693430. |
we report on changes in weight, and other risk factors for heart disease, in thirty-three schizophrenia patients who agreed to switch from other antipsychotics to aripiprazole in an open, flexible-dose, eight-week trial. |
2011-08-30 |
2023-08-12 |
Not clear |
| Corrado Barbui, Simone Accordini, Michela Nosè, Scott Stroup, Marianna Purgato, Francesca Girlanda, Eleonora Esposito, Antonio Veronese, Michele Tansella, Andrea Ciprian. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. Journal of clinical psychopharmacology. vol 31. issue 3. 2011-08-29. PMID:21508849. |
aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. |
2011-08-29 |
2023-08-12 |
Not clear |
| Corrado Barbui, Simone Accordini, Michela Nosè, Scott Stroup, Marianna Purgato, Francesca Girlanda, Eleonora Esposito, Antonio Veronese, Michele Tansella, Andrea Ciprian. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. Journal of clinical psychopharmacology. vol 31. issue 3. 2011-08-29. PMID:21508849. |
this multisite study was conducted to compare the efficacy and tolerability of combination treatment with clozapine plus aripiprazole versus combination treatment with clozapine plus haloperidol in patients with schizophrenia who do not have an optimal response to clozapine. |
2011-08-29 |
2023-08-12 |
Not clear |
| Corrado Barbui, Simone Accordini, Michela Nosè, Scott Stroup, Marianna Purgato, Francesca Girlanda, Eleonora Esposito, Antonio Veronese, Michele Tansella, Andrea Ciprian. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. Journal of clinical psychopharmacology. vol 31. issue 3. 2011-08-29. PMID:21508849. |
these results suggest that augmentation of clozapine with aripiprazole offers no benefit with regard to treatment withdrawal and overall symptoms in schizophrenia compared with augmentation with haloperidol. |
2011-08-29 |
2023-08-12 |
Not clear |
| Makoto Ishitobi, Hirotaka Kosaka, Ken-Ichi Shukunami, Tetsuhito Murata, Yuji Wad. Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia". Journal of clinical psychopharmacology. vol 31. issue 3. 2011-08-29. PMID:21532377. |
comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia". |
2011-08-29 |
2023-08-12 |
Not clear |
| Cliff McKinney, Kimberly Ren. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clinical psychology review. vol 31. issue 3. 2011-08-23. PMID:21130552. |
however, with exception of using risperidone (i.e., for the management of irritability associated with autism, manic and mixed episodes associated with bipolar i disorder, and schizophrenia) and aripiprazole (i.e., for manic and mixed episodes associated with bipolar i disorder and schizophrenia), the food and drug administration (fda) has not approved the use of aams in children and adolescents. |
2011-08-23 |
2023-08-12 |
Not clear |
| Takeshi Suzuki, Kazuo Mihara, Akifumi Nakamura, Goyo Nagai, Shoko Kagawa, Kenji Nemoto, Ikuya Ohta, Hajime Arakaki, Tsukasa Uno, Tsuyoshi Kond. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic drug monitoring. vol 33. issue 1. 2011-08-10. PMID:21157400. |
effects of the cyp2d6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in japanese patients with schizophrenia. |
2011-08-10 |
2023-08-12 |
human |